Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
May 7, 2007

Stem Cell Innovations to Perform Compound Validation for H. Lundbeck

  • Stem Cell Innovations entered into an agreement to examine hepatic metabolism of a set of H. Lundbeck compounds using its C3A human liver cell-line.

    "This new collaboration shows the expanding acceptance of our C3A cell-line as an excellent platform to study human liver function," notes Stem Cell Innovations' CEO James Kelly. "Our protected C3A cell system has intact human liver machinery, is robust, and is thoroughly quality controlled, all the prerequisites for larger-scale in vitro efficacy and safety programs."      

    C3A is SCI's human liver cell line, originally developed for use in an artificial liver used to support patients waiting for transplantation. The cells exhibit a wide variety of human liver functions and are ideal for use in examining the effects of new drugs on the human liver, according to the company.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »